Rheumatoid arthritis (RA) is a chronic autoimmune disease characterized by inflammation and joint damage. Synovial hypoxia (low oxygen) is a specific feature of RA and plays an important role in the formation and progression of this disease. “Hypoxia induces angiogenesis, inflammation, apoptosis, cartilage erosion, abnormal energy metabolism and oxidative damage” Hyperbaric oxygen therapy (HBOT) can reverse hypoxic conditions throughout the body and therefore can help effectively halt the pathogenesis of RA. In this study, the animal model of RA was evaluated with hyperbaric oxygen therapy; whereby, male mice received a total of 10 daily hyperbaric sessions at 2.4 ATA (90 minutes of pure oxygen and two 5 minute air breaks). This group of mice that received HBOT had a significant reduction in the mouse model of arthritis, along with the reduction in disease-progressive inflammatory markers. After evaluating all the data collected from this study, the researchers concluded that a 10 day course of hyperbaric therapy in 12 days can be “an alternative therapy that is considered successful in reducing morbidity and mortality of RA patients” <view study> In addition to the study above, a new pilot study published in the journal of Clinical Rheumatology on September 16, 2020 also found Hyperbaric oxygen therapy to be effective for joint pain in patients with RA <view this study> Read Less

This study evaluated 20 Ulcerative Colitis (UC) patients that were hospitalized for moderate to severe flares and treated with either a 3 or 5 day course of hyperbaric oxygen therapy (HBOT, at 2.4 atmospheres, 90 minutes with two air breaks) in addition to intravenous steroids. By Day 3, there were significant reductions in stool frequency, rectal bleeding, and overall inflammation. A more significant reduction in disease activity was observed with 5 days vs 3 days of HBOT. Thus researchers concluded that an optimal clinical response is achieved with 5 days of hyperbaric oxygen therapy. <view study> Read Less

Hyperbaric oxygen therapy could “significantly affect the expression levels of IL-12p40, MIP-1β, PDGF-BB, and IL-1Ra, indicating that the effects of HBO therapy are associated with the attenuation of inflammatory responses”. <view study> Read Less

Complex regional pain syndrome (CRPS) can be a debilitating disorder associated with severe pain and disability characterized by both auto-inflammatory and autoimmune features. This publication was a case report of a patient with long-standing CRPS that had a dramatic response to a course of hyperbaric oxygen therapy (HBOT) and was able to successfully lower their prednisone dosage. Symptoms reemerged a few months later so a second course of hyperbaric therapy was prescribed. Similarly to the first course, the patient improved symptomatically and was able to once again lower the dose prednisone. “This case is unique in that it shows that HBOT can be effective in long-standing CRPS, both initially, and for subsequent flares, and adds to the evidence supporting HBOT as a potential treatment for this condition” <view study> Read Less

From Wuhan China — promising results have just been published in a preliminary report by Dr. Zhong Yangling for the treatment of 5 COVID-19 patients (2 of which were critical and 3 were severe) with hyperbaric therapy at the Department of Hyperbaric Oxygen in Wuhan Yangtze River Shipping General Hospital. In this report, hyperbaric oxygen was added to the current comprehensive treatments being performed at the hospital for COVID-19 affected patients, with a dose of 90-120 minutes at treatment pressures of 1.4 to 1.6 ATA. The results were very encouraging as these 5 patients received significant therapeutic benefits, including rapid relief of symptoms after the first session. The rationale for adding this procedure is to help combat the progressive hypoxemia (low blood oxygen levels) that COVID-19 can cause. Hyperbaric oxygen has the ability to add a substantial supply of extra oxygen into the bloodstream and therefore can help during these times of hypoxemia. Hypoxemia is the key determinant to the deterioration of patients seen with COVID-19. The virus attacks the lungs and causes inflammation and the body has a difficult time getting enough oxygen transferred from the lungs into the body. This progressive hypoxemia leads to the increase in mortality rates as patients can become critically ill. At this time, they are typically in compete reliance on ventilators to help restore oxygen levels, to keep them alive, while the body fights the virus and repairs the lung damage. Advantages of hyperbaric oxygen for treatment of progressive hypoxemia is that the higher pressure environment allows greater levels of oxygen to pass through the thickened and inflamed lung tissue into the blood stream; thereby directly treating the hypoxemia. Add to this, the greater solubility of oxygen in the blood (in hyperbaric conditions) and it’s now easy to see why all 5 patients reported dramatic relief of their symptoms — Dr. Zhong reported that after the first session of hyperbaric oxygen, symptoms such as dyspnea (shortness of breath) and chest pain were reduced. After the second session, the respiratory rate decreased gradually and the shortness of breath (after movement) relieved slowly. To correlate with these subjective results, Dr. Zhong was able to objectively chart a significant upward trend of oxygen levels, day by day. In addition, lung inflammation was re-evaluated though CT scan and all 5 patients significantly improved. It should be noted, that hyperbaric oxygen is not a treatment for the COVID-19 virus and this report should NOT lead people to look for hyperbaric chambers for treating the virus, particulary within private centers that are not equipped for treating infectious diseases. However, this is a very important paper outlining the potential clinical role that hyperbaric therapy can play in the symptomatic relief of hypoxemia that is seen in the COVID-19 affected population. Hopefully, this will lead the medical community to take a much harder look at integrating hyperbaric therapy and utilizing its key physiological benefits (ie, reducing hypoxia). In turn, this could lead to a much larger demand for the use of hyperbaric chambers in hospitals and infectious disease centers to coexist as supportive therapy, during these critical stages. Deploying hyperbaric chambers in this manner could offer a major lifeline support to patients, while aggressive medical treatments are being administered in the hospital setting. This applies to both current hospital-type chambers and portable hyperbaric chambers as these chambers can be performed in the open area of the hospital. Hospital chambers — According to Dr. Zhong, these chambers can help “improve the treatment efficiency, reduce the medical pressure and the risk of infection, and decrease the mortality rate of critical patients”. With the limited supply of ventilators, hyperbaric chambers can offer valuable relief. Hyperbaric Oxygen Department of Wuhan Changjiang Shipping General Hospital has established a complete infection control procedures and measures for hyperbaric treatment of patients with coronavirus. If followed, this could lead to a widespread movement of hyperbaric chambers to help in areas where the local demand is too great from community infection. In Wuhan, Huoshenshan hospitals are not equipped with hyperbaric chambers so construction of a new hyperbaric oxygen chamber system started at Huoshenshan Hospital and is being installed and commissioned for use within 15 days! Portable chambers — These chambers are typically operated at lower pressures of 1.3 ATA and can have physiological benefits in reducing hypoxemia. Of note, Dr. Zhong also tested 1.2 to 1.4 ATA and found that the oxygen levels were still kept in a high level and this was even with ambient air application. Again, as a supportive therapy, this could be very valuable for helping to maintain oxygen levels. Here in the United States, these types of chambers have been making steady growth in the hyperbaric industry (over the past 20 years) and fueled lately by high profile athletes promoting its benefits. As this industry grows, many private hyperbaric centers are now writing prescriptions for patients for home use. This may help during times of isolation and the early infection period where patients are told to stay at home until symptoms become severe and hypoxemia begins to take its toll. To summarize, this publication by Dr. Zhong should encourage us to look into hyperbaric medicine in a new way, when it comes to severe respiratory diseases caused by coronavirus. Since this study, Dr. Zhong has now treated a total of 35 COVID-19 cases. As this pandemic continues, we do not know how much of the public will be affected and the extra load that will impact our medical system. What we do know is that this virus primarily targets the lung tissue, causing severe inflammation and hypoxemia. Hyperbaric oxygen may offer a valuable therapeutic delivery of oxygenation during times of hypoxemia. More research should be looked into this. Dsiclaimer -- is very important that this article is not construed as an article that promotes treating COVID-19 with hyperbaric therapy. Anyone who has been diagnosed with COVID-19 or suspected of having this infection , should follow the CDC guidelines (and not seek treatments in a hyperbaric chamber as an alternative). This is purely educational material on the new preliminary report published from Wuhan China <view report> Read Less